Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-03-12

Clinical Trial Update: Vandetanib to Treat Advanced Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of Vandetanib for advanced Clear cell renal cell carcinoma was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vandetanib (vandetanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Clear Cell Renal Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2012-03-12